Business Wire

KnowBe4 Pioneers Training AI Agents for the Next Generation Workforce

7.10.2025 15:00:00 EEST | Business Wire | Press release

Share

KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human and AI agent risk management, today announced breakthrough innovations that train both people and AI agents to defend against evolving cyber threats. According to Gartner, forty percent of enterprise applications will be integrated with task-specific AI agents by the end of 2026, up from less than 5% today. These AI agents are the new targets for theft, adversarial manipulation and misuse, which emphasizes the importance of employee AI literacy.

For years, the human element has been involved in over 60% of breaches, including social engineering as one of the top attack vectors, confirmed in reports such as the 2025 Verizon Data Breach Investigations Report. Given the prevalence of the human element in breaches, smarter defenses that address the dynamic between humans and AI agents is integral to build a solid cybersecurity defense strategy.

“We are delivering adaptive, personalized, AI-driven defenses today to safeguard the next generation global workforce,” said Bryan Palma, CEO, KnowBe4. “We do both, guard humans against AI-driven attacks and shield AI systems from exploitation. KnowBe4 is uniquely positioned to protect enterprise AI agents by securing the essential human-agent interaction layer. As AI becomes both a powerful tool and a potential target, safeguarding this interaction point is crucial.”

Cyber threats are growing more sophisticated through AI, but AI itself is also becoming a tool and a high-value target. While most solutions focus solely on defending at the gateway layer, KnowBe4’s HRM+ goes further, delivering true defense-in-depth. Built on 15 years of user behavior and threat intelligence data, the platform ensures that protection extends beyond the edge, securing every layer of interaction, from the productivity environment to the individual user and the AI agents themselves. This layered approach provides resilience that no other platform currently matches and includes:

  • Agent-Safe Behavior Training: Just as employees learned to spot a malicious link, they must now learn how to safely interact with and oversee AI agents.
  • Prompt Injection & Manipulation Defense: Simulated attacks train global workforces to identify and resist adversarial inputs designed to hijack enterprise AI agents.
  • Risk Scoring for Agent Interactions: Extending the industry-leading Risk Score to measure susceptibility to agent misuse provides comprehensive risk quantification.

A KnowBe4 customer credits the company with being at the forefront of evolving cybersecurity needs: "Threats change and adapt far too often. KnowBe4 knows this and adapts their training to meet the current threats. AI Defense Agents in particular help quickly adapt to the evolving threat landscape." KnowBe4 is the pioneer of AI-driven human risk management. View previous released capabilities and watch the demo presented at the KB4-CON Conference in April 2025 here.

About KnowBe4

KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organizations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven ‘best-of-suite’ platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilizes personalized and relevant cybersecurity protection content, tools and techniques to mobilize workforces to transform from the largest attack surface to an organization’s biggest asset. More info at knowbe4.com.

Follow KnowBe4 on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007076214/en/

Contacts

Media Contact
Amanda Tarantino
Head of Public Relations, Americas
KnowBe4
pr@knowbe4.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye